[go: up one dir, main page]

ECSP17010156A - Compuestos aminopirimidinilo como inhibidores jak - Google Patents

Compuestos aminopirimidinilo como inhibidores jak

Info

Publication number
ECSP17010156A
ECSP17010156A ECIEPI201710156A ECPI201710156A ECSP17010156A EC SP17010156 A ECSP17010156 A EC SP17010156A EC IEPI201710156 A ECIEPI201710156 A EC IEPI201710156A EC PI201710156 A ECPI201710156 A EC PI201710156A EC SP17010156 A ECSP17010156 A EC SP17010156A
Authority
EC
Ecuador
Prior art keywords
jak inhibitors
aminopyrimidinyl
compounds
aminopyrimidinyl compounds
jak
Prior art date
Application number
ECIEPI201710156A
Other languages
English (en)
Inventor
Ariamala Gopalsamy
Betsy Susan Pierce
Brian S Gerstenberger
Liying Zhang
Jean-Baptiste Telliez
Zhao-Kui Wan
Eddine Saiah
Ivan Viktorovich Efremov
Andrew Fensome
Li Xing
John I Trujillo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17010156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP17010156A publication Critical patent/ECSP17010156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N7/00—Television systems
    • H04N7/18—Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
    • H04N7/188—Capturing isolated or intermittent images triggered by the occurrence of a predetermined event, e.g. an object reaching a predetermined position

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)

Abstract

Un compuesto que tiene una estructura (ver gráfico) o una sal farmacéuticamente aceptable del mismo.
ECIEPI201710156A 2014-08-21 2017-02-16 Compuestos aminopirimidinilo como inhibidores jak ECSP17010156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462039969P 2014-08-21 2014-08-21

Publications (1)

Publication Number Publication Date
ECSP17010156A true ECSP17010156A (es) 2017-11-30

Family

ID=54148580

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201710156A ECSP17010156A (es) 2014-08-21 2017-02-16 Compuestos aminopirimidinilo como inhibidores jak

Country Status (48)

Country Link
US (5) US9663526B2 (es)
EP (1) EP3183247B9 (es)
JP (1) JP6218260B2 (es)
KR (1) KR101877189B1 (es)
CN (1) CN107074867B (es)
AP (1) AP2017009748A0 (es)
AR (1) AR101599A1 (es)
AU (1) AU2015304883B2 (es)
BR (1) BR112017003054B1 (es)
CA (1) CA2900855C (es)
CL (1) CL2017000406A1 (es)
CO (1) CO2017001603A2 (es)
CR (1) CR20170066A (es)
CU (1) CU24435B1 (es)
CY (1) CY1119771T1 (es)
DK (1) DK3183247T3 (es)
DO (1) DOP2017000048A (es)
EA (1) EA032609B1 (es)
EC (1) ECSP17010156A (es)
ES (1) ES2655971T3 (es)
GE (1) GEP20197003B (es)
GT (1) GT201700035A (es)
HR (1) HRP20171913T1 (es)
HU (1) HUE035553T2 (es)
IL (1) IL250709B (es)
LT (1) LT3183247T (es)
MA (1) MA40587A (es)
MD (1) MD4800C1 (es)
ME (1) ME02856B (es)
MX (1) MX372997B (es)
MY (1) MY192109A (es)
NI (1) NI201700020A (es)
NO (1) NO2721710T3 (es)
NZ (1) NZ729005A (es)
PE (1) PE20171177A1 (es)
PH (1) PH12017500276A1 (es)
PL (1) PL3183247T3 (es)
PT (1) PT3183247T (es)
RS (1) RS56807B1 (es)
SG (1) SG11201700957WA (es)
SI (1) SI3183247T1 (es)
SV (1) SV2017005384A (es)
TN (1) TN2017000044A1 (es)
TW (1) TWI583681B (es)
UA (1) UA117976C2 (es)
UY (1) UY36275A (es)
WO (1) WO2016027195A1 (es)
ZA (1) ZA201701005B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
JP6577958B2 (ja) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
NO2721710T3 (es) 2014-08-21 2018-03-31
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
JP2018527362A (ja) 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換されたヘテロアリール化合物および使用方法
ES2873895T3 (es) 2015-10-09 2021-11-04 Boehringer Ingelheim Int Compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
MX377180B (es) 2016-04-28 2025-03-07 Theravance Biopharma R&D Ip Llc Compuestos de pirimidina como inhibidores de la quinasa jak.
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. POLYTHERAPY OF DISORDERS AND INFLAMMATORY EYE DISEASES
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
EP3848370B1 (en) * 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN109422753B (zh) * 2017-09-03 2021-12-31 上海美志医药科技有限公司 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
CN111247142B (zh) 2017-10-27 2022-12-02 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的嘧啶化合物
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
AU2019216522A1 (en) 2018-02-05 2020-08-27 Alkermes, Inc. Compounds for the treatment of pain
CA3106470A1 (en) 2018-07-17 2020-01-23 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
TWI850262B (zh) 2018-09-25 2024-08-01 美商卡都瑞恩醫藥公司 胺基嘧啶化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
TW202033198A (zh) * 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
WO2020165788A1 (en) * 2019-02-15 2020-08-20 Pfizer Inc. Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
CN111658628B (zh) * 2019-03-08 2022-03-01 中国科学院动物研究所 Gli2抑制剂的用途以及抑制gli2的化合物的筛选方法
KR102737181B1 (ko) 2019-03-14 2024-12-02 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. Jak 억제제 및 그 제조방법과 의약분야에서의 응용
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020203609A1 (ja) 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CA3135383A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors
US11439641B2 (en) 2019-04-24 2022-09-13 Theravance Biopharma R&D Ip, Llc Pyrimidine JAK inhibitors for the treatment of skin diseases
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
JP2022543690A (ja) * 2019-08-09 2022-10-13 中国医▲薬▼研究▲開▼▲発▼中心有限公司 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法、及びその薬学的使用
CN114667148A (zh) * 2019-09-11 2022-06-24 辉瑞公司 用jak抑制剂治疗汗腺炎
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN110862376A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113372351A (zh) * 2020-03-10 2021-09-10 明慧医药（杭州）有限公司 一类jak激酶抑制剂及其制备和应用
CN113372364B (zh) * 2020-03-10 2024-05-31 明慧医药（上海）有限公司 一类jak激酶抑制剂及其制备和应用
KR20220154722A (ko) * 2020-03-17 2022-11-22 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN113698403B (zh) * 2020-05-21 2022-06-28 南京亘泰医药技术有限公司 (1r,4r,7r)-7-氨基-2-氮杂双环[2,2,1]庚烷衍生物及制备方法
WO2021249367A1 (zh) * 2020-06-09 2021-12-16 苏州晶云药物科技股份有限公司 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
TWI782599B (zh) * 2020-07-02 2022-11-01 美商輝瑞股份有限公司 胺基嘧啶基衍生物
TWI785660B (zh) * 2020-07-02 2022-12-01 美商輝瑞大藥廠 嘧啶基-3,8-二氮雜雙環[3.2.1]辛烷基甲酮衍生物及其鹽之製備
US20230277537A1 (en) 2020-07-17 2023-09-07 Pfizer Inc. Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological condition
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
EP4279485A4 (en) * 2021-01-14 2024-12-25 The National Institutes of Pharmaceutical R&D Co., Ltd Bridged heterocyclyl-substituted pyrimidine compounds, preparation method and medical use thereof
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
KR20230159839A (ko) 2021-03-15 2023-11-22 메이즈 테라퓨틱스, 인코퍼레이티드 글리코겐 합성효소 1(gys1)의 저해제 및 이의 사용 방법
CN113999239B (zh) * 2021-07-14 2022-11-11 上海凌富药物研究有限公司 一种二氮杂桥化合物的合成方法
CN113698409B (zh) * 2021-08-10 2022-07-19 上海凌凯医药科技有限公司 一种多用途的二氮杂双环类化合物、制备方法及在合成药物中的应用
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
WO2023041061A1 (zh) * 2021-09-17 2023-03-23 江苏恒瑞医药股份有限公司 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN114181097B (zh) * 2021-12-10 2024-05-14 广东嘉博制药有限公司 一种盐酸甲氧明的合成方法
CN118973579A (zh) * 2022-03-17 2024-11-15 辉瑞公司 用于治疗汗腺炎的方法、剂量方案和组合物
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
CN118005609B (zh) * 2022-11-09 2025-06-17 沈阳药科大学 2-氨基嘧啶类化合物及其用途
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
WO2024148186A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法
CN116903592A (zh) * 2023-07-13 2023-10-20 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
CN117756822B (zh) * 2023-12-20 2025-04-18 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶氨基类化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
JP4891068B2 (ja) 2004-03-31 2012-03-07 第一三共株式会社 １，２−シス−２−フルオロシクロプロパン−１−カルボン酸エステル類の製造法
US7803822B2 (en) 2005-04-06 2010-09-28 Takeda Pharmaceutical Company Limited Triazole derivative and use thereof
WO2007042298A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007084557A2 (en) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of janus kinases
JP2010503649A (ja) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ ピリミジン誘導体
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
JP2010523522A (ja) * 2007-04-02 2010-07-15 パラウ・フアルマ・ソシエダツド・アノニマ Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
CN102089289A (zh) 2008-07-16 2011-06-08 弗·哈夫曼-拉罗切有限公司 用于治疗心血管疾病的新的杂环基化合物
WO2010075273A1 (en) * 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
TR201807973T4 (tr) 2011-09-22 2018-06-21 Merck Sharp & Dohme Janus kinaz inhibitörleri olarak siyanometilpirazol karboksamidler.
WO2013090837A2 (en) 2011-12-16 2013-06-20 Invista North America S.A.R.L. METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
NO2721710T3 (es) 2014-08-21 2018-03-31

Also Published As

Publication number Publication date
AP2017009748A0 (en) 2017-02-28
GEP20197003B (en) 2019-07-25
PE20171177A1 (es) 2017-08-22
BR112017003054A2 (pt) 2017-11-21
PT3183247T (pt) 2018-01-18
NZ729005A (en) 2020-06-26
EP3183247B1 (en) 2017-11-29
CR20170066A (es) 2017-07-17
CO2017001603A2 (es) 2017-05-10
UY36275A (es) 2016-04-01
JP6218260B2 (ja) 2017-10-25
US11197867B2 (en) 2021-12-14
US20170239264A1 (en) 2017-08-24
MX372997B (es) 2020-04-06
KR20170036109A (ko) 2017-03-31
BR112017003054B1 (pt) 2023-04-11
CU20170015A7 (es) 2017-06-05
TN2017000044A1 (en) 2018-07-04
EP3183247A1 (en) 2017-06-28
MA40587A (fr) 2017-06-28
CY1119771T1 (el) 2018-06-27
CA2900855A1 (en) 2016-02-21
US9663526B2 (en) 2017-05-30
US20210377495A1 (en) 2021-12-02
HRP20171913T1 (hr) 2018-02-09
SI3183247T1 (en) 2018-02-28
US20200038409A1 (en) 2020-02-06
PL3183247T3 (pl) 2018-03-30
MD4800B1 (ro) 2022-03-31
IL250709A0 (en) 2017-04-30
KR101877189B1 (ko) 2018-07-10
MD20170016A2 (ro) 2017-08-31
US20200330477A1 (en) 2020-10-22
ZA201701005B (en) 2019-07-31
UA117976C2 (uk) 2018-10-25
ES2655971T3 (es) 2018-02-22
US10463675B2 (en) 2019-11-05
ME02856B (me) 2018-04-20
IL250709B (en) 2019-05-30
MY192109A (en) 2022-07-27
PH12017500276A1 (en) 2017-07-03
LT3183247T (lt) 2018-01-25
CA2900855C (en) 2022-03-15
JP2017524022A (ja) 2017-08-24
EA032609B1 (ru) 2019-06-28
DOP2017000048A (es) 2017-06-30
TWI583681B (zh) 2017-05-21
CU24435B1 (es) 2019-09-04
TW201609706A (zh) 2016-03-16
SG11201700957WA (en) 2017-03-30
EP3183247B9 (en) 2018-07-25
SV2017005384A (es) 2017-07-10
CL2017000406A1 (es) 2017-10-06
MX2017002241A (es) 2017-05-03
US10980815B2 (en) 2021-04-20
MD4800C1 (ro) 2022-10-31
ES2655971T9 (es) 2018-09-14
US20160052930A1 (en) 2016-02-25
CN107074867A (zh) 2017-08-18
NI201700020A (es) 2017-05-02
EA201700077A1 (ru) 2017-07-31
NO2721710T3 (es) 2018-03-31
AR101599A1 (es) 2016-12-28
WO2016027195A1 (en) 2016-02-25
CN107074867B (zh) 2019-10-22
HUE035553T2 (hu) 2018-05-02
GT201700035A (es) 2019-10-10
RS56807B1 (sr) 2018-04-30
DK3183247T3 (en) 2018-01-15
AU2015304883A1 (en) 2017-03-02
AU2015304883B2 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
LT3468966T (lt) Menino-mll sąveikos inhibitoriai
EA201891211A1 (ru) Ингибиторы cxcr2
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP3319606A4 (en) PHARMACEUTICAL COMPOUND
HUE052421T2 (hu) (2S)-N-[(1S)-1-ciano-2-feniletil]-l,4-oxazepan-2-karboxamidok dipeptidil-peptidáz I inhibitorokként
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3235819T3 (da) Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
BR112016030730A2 (pt) Composto
EP3349750A4 (en) PHARMACEUTICAL COMPOUND
EP3533799A4 (en) CONNECTION
HUE066987T2 (hu) Szelektív il-6-transz-szignalizációt gátló szert tartalmazó készítmények
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
BR112017002139A2 (pt) ?método para preparar um composto?
EP3421542A4 (en) CONNECTION
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
TH1501006857A (th) อนุพันธ์ไบโพราโซลสำหรับใช้เป็นสารยับยั้ง jak
IT201600110418A1 (it) Procedimento per generare un database utilizzando una lookup table.